Overview
I first became interested in clinical immunology as a medical student studying autoimmune inflammatory eye disease at the National Institutes of Health. Since then, I have been inspired to understand what causes autoimmunity and immune deficiency disorders in order to improve the quality of life for my patients. I see patients with multiple complex immune disorders with particular expertise in autoimmune and Rheumatoid arthritis, primary Sjogren's syndrome, and the immunodeficiency disorders Common Variable Immunodeficiency (CVID), Adenosine Deaminase Deficiency (ADA) disorders, and WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis). My research investigates immune targets that may impact either the development of immune disease or identify new therapies for patients. The goal is to help us understand why and how immunologic diseases develop so that we may better treat them.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Evolving spectrum of adenosine deaminase (ADA) deficiency: Assessing genotype pathogenicity according to expressed ADA activity of 46 variants.
Journal Article J Allergy Clin Immunol · January 2025 BACKGROUND: Deficiency of adenosine deaminase (ADA or ADA1) has broad clinical and genetic heterogeneity. Screening techniques can identify asymptomatic infants whose phenotype and prognosis are indeterminate, and who may carry ADA variants of unknown sign ... Full text Link to item CitePurine Nucleoside Phosphorylase Deficiency Presenting with Neurological Involvement: A Case Report of Two Siblings
Journal Article Asthma Allergy Immunology · August 1, 2024 Purine nucleoside phosphorylase (PNP) deficiency is a rare immunodeficiency syndrome generally characterized by profound T cell deficiency and variable B cell function. More than half of PNP-deficient patients present with neurological dysfunction, with ma ... Full text CiteA novel transmembrane CXCR4 variant that expands the WHIM genotype-phenotype paradigm.
Journal Article Blood Adv · July 23, 2024 Full text Link to item CiteRecent Grants
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infec
Clinical TrialPrincipal Investigator · Awarded by X4 Pharmaceuticals · 2025 - 2029HZNP-DAZ-303: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dazodalibep in participants with Sjogren's syndrome with moderate-to-severe symptom state.
Clinical TrialPrincipal Investigator · Awarded by Horizon Therapeutics Ireland DAC · 2024 - 2026HZNP-DAZ-301: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dazodalibep in participants with Sjogren's syndrome with moderate-to-severe systemic disease activity.
Clinical TrialPrincipal Investigator · Awarded by Horizon Therapeutics Ireland DAC · 2024 - 2026View All Grants